ERBB2 and breast cancer: AQP inhibition also cooperatively elicits antitumorigenic responses in combination with tamoxifen and fulvestrant in murine ER+ PyMT and human ER+/HER2− MCF7 breast cancer cell lines (Figure 5B,C).